Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia
Oral Leukoplakia
About this trial
This is an interventional treatment trial for Oral Leukoplakia
Eligibility Criteria
Inclusion Criteria:
Clinically and histologically proven cases of leukoplakia associated with tobacco.
With age 18 years and above. Willing and able to participate in the study and signed informed consent.
Exclusion Criteria:
Patients suspicious of malignant transformation of the lesion with frank ulceration or growth.
Patients consuming or have consumed drugs for treatment of leukoplakia.
Patients who have red or white lesions persisting after radiotherapy treatment
Patients with acquired and congenital immunodeficiency disorders like AIDS, chemotherapy, addiction to injectable opioids and any other significant medical or systemic or autoimmune conditions.
Pregnancy or lactation phase.
Known allergy to melatonin.
Sites / Locations
- Post graduate institute of dental sciencesRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Trial group
Control Group
Intervention : Topical Melatonin(3%) at dosage of 15 mg once daily
Intervention : Placebo once daily